Kozłowski, M <br/><br/>
Serum tissue inhibitor of metalloproteinase 1 (TIMP-1) and vascular endothelial growth factor A (VEGF-A) are associated with prognosis in esophageal cancer patients.  [electronic resource] 

 -  Advances in medical sciences  2013 
 - 227-34 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1898-4002 
<br/><br/><label>Standard No.: </label>10.2478/ams-2013-0017  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--metabolism<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Biomarkers, Tumor--blood<br/>Carcinoma, Squamous Cell--metabolism<br/>Disease-Free Survival<br/>Enzyme-Linked Immunosorbent Assay<br/>Esophageal Neoplasms--metabolism<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Lymphatic Metastasis<br/>Male<br/>Middle Aged<br/>Neoplasm Staging<br/>Prognosis<br/>Tissue Inhibitor of Metalloproteinase-1--blood<br/>Vascular Endothelial Growth Factor A--blood